Form 8-K - Current report:
SEC Accession No. 0001213900-25-051361
Filing Date
2025-06-05
Accepted
2025-06-05 08:01:07
Documents
14
Period of Report
2025-06-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244733-8k_estrella.htm   iXBRL 8-K 29286
2 PRESS RELEASE DATED AS OF JUNE 5, 2025 ea024473301ex99-1_estrella.htm EX-99.1 9988
  Complete submission text file 0001213900-25-051361.txt   255921

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE esla-20250605.xsd EX-101.SCH 3862
4 XBRL DEFINITION FILE esla-20250605_def.xml EX-101.DEF 26752
5 XBRL LABEL FILE esla-20250605_lab.xml EX-101.LAB 36957
6 XBRL PRESENTATION FILE esla-20250605_pre.xml EX-101.PRE 25376
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0244733-8k_estrella_htm.xml XML 6079
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 251025050
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)